September 14, 2018
March 28, 2018Full List »
Kara L. Davis, D.O. is an Assistant Professor of Pediatrics at Stanford University in the Division of Hematology and Oncology. Dr. Davis is the Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases. Dr. Davis received her Bachelor of Arts from Pennsylvania State University and Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine. She completed her Pediatrics training at Thomas Jefferson University in Philadelphia, PA and Oncology/Hematology Fellowship at Stanford. Dr. Davis’ research focuses on applying single-cell, high-parameter technologies to the study of childhood cancers to identify cell populations and their features predictive of adverse clinical outcomes. Dr. Davis and colleagues have developed a developmental classifier for analysis of B-cell acute lymphoblastic leukemia (ALL) and using this tool, uncovered a cell population of leukemic pre-B cells present at diagnosis that was highly predictive of future relapse in children. Using these tools, Dr. Davis’ group is investigating the impact of standard drug treatment or novel immunotherapies on these resistant cells and determining how they are resistant. Using high dimensional imaging techniques, the group is investigating childhood solid tumors to examine tumor cell heterogeneity and the immune microenvironment. Dr. Davis has also been instrumental in leading clinical trials utilizing the immune system to treat relapsed leukemia and solid tumors. Dr. Davis was the institutional PI for the pivotal trial which led to FDA approval of the first cellular therapy for cancer, chimeric antigen T-cells. She is a co-investigator on the Stanford bi-specific CAR trial for relapsed or refractory leukemia and leads the effort in correlative biology studies. She also co-leads the COG study ADVL1412 studying the role of checkpoint inhibition in pediatric cancer.